Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Charles Soria

Showing results (1-10 of 536) with videos related to

Pageof 54
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trialJean-Charles Soria
Clinical Advances in Hematology & Oncology : H&O|March 8, 2019
Moving from academia to industry in the field of oncologyJean-Charles Soria
Revue De Pneumologie Clinique|January 24, 2007
[Perspectives and future developments of epidermal growth factor receptors inhibitors]Jean-Charles Soria
European Journal of Cancer (Oxford, England : 1990)|May 11, 2011
Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?Jean-Charles Soria
Medecine Sciences : M/S|October 10, 2017
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]Stéphane Champiat, Jean-Charles Soria
Bulletin Du Cancer|May 19, 2005
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
La Revue Du Praticien|April 26, 2007
[Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient]Benjamin Besse, Jean-Charles Soria
Nature Clinical Practice. Oncology|September 7, 2006
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?Giannis Mountzios, Jean-Charles Soria
Bulletin Du Cancer|January 24, 2007
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?]Julien Grenier, Jean-Charles Soria
Bulletin Du Cancer|July 9, 2004
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
Pageof 54

Showing results (1-10 of 536) with videos related to

Sort By:
Pageof 54
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trialJean-Charles Soria
Clinical Advances in Hematology & Oncology : H&O|March 8, 2019
Moving from academia to industry in the field of oncologyJean-Charles Soria
Revue De Pneumologie Clinique|January 24, 2007
[Perspectives and future developments of epidermal growth factor receptors inhibitors]Jean-Charles Soria
European Journal of Cancer (Oxford, England : 1990)|May 11, 2011
Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?Jean-Charles Soria
Medecine Sciences : M/S|October 10, 2017
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]Stéphane Champiat, Jean-Charles Soria
Bulletin Du Cancer|May 19, 2005
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
La Revue Du Praticien|April 26, 2007
[Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient]Benjamin Besse, Jean-Charles Soria
Nature Clinical Practice. Oncology|September 7, 2006
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?Giannis Mountzios, Jean-Charles Soria
Bulletin Du Cancer|January 24, 2007
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?]Julien Grenier, Jean-Charles Soria
Bulletin Du Cancer|July 9, 2004
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
Pageof 54